Core Viewpoint - 康诺亚-B's stock price increased by over 4% following the announcement that its self-developed drug, 康悦达 (司普奇拜单抗), has been included in the National Basic Medical Insurance Drug List for 2025, effective from January 1, 2026 [1] Group 1: Company Developments - 康诺亚 announced that 康悦达 (司普奇拜单抗) is the first domestically developed IL-4Rα humanized monoclonal antibody approved for market, targeting type 2 inflammatory diseases through dual blockade of the IL-4/IL-13 signaling pathway [1] - 康悦达 has received approval for three indications: moderate to severe atopic dermatitis in adults inadequately controlled by topical medications, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate to severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids combined with antihistamines [1] Group 2: Market Impact - Following the announcement, 康诺亚-B's stock rose by 4.23%, reaching a price of 61.6 HKD, with a trading volume of 1.3244 million HKD [1]
康诺亚-B高开逾4% 司普奇拜单抗注射液纳入国家基本医疗保险药品目录